Medical News

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Multiple Myeloma, Hematologic Cancers

Sequencing Offers Clues to Progression Toward Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn’t show outward symptoms.

Medicine

Channels:

multiple myelmoma, Hematologic Cancers

Tracking How Multiple Myeloma Evolves by Sequencing DNA in the Blood

Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments.

Medicine

Channels:

Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

• Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis • Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

Medicine

Channels:

Lymphoma, Physical Activity, Survival, Medical Research

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 11-Dec-2017 7:45 PM EST

Medicine

Channels:

IL2, Cancer

Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

Medicine

Channels:

CAR-T cell therapy, Lymphoma

Landmark CAR-T Cancer Study Published in the New England Journal of Medicine

CAR-TInfographic.jpg

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Medicine

Channels:

apple watch, cancer patient reported outcomes, emoji, Survivorship, ASH2017, Dr. Carrie Thompson

Mayo Clinic Study Finds Emojis Promising Tool for Tracking Cancer Patients’ Quality of Life

In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients’ physical, emotional and overall quality of life. Researchers found that using iPhones and Apple Watches were favored by patients, and the technology helped collect study data accurately and efficiently.

Medicine

Channels:

Immunotherapy Strategy Could Be Beneficial for Relapsed Acute Myeloid Leukemia, Preliminary Data Show

Zeidnerpreferred3.jpg

Researchers present their preliminary results from the ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on Saturday, Dec. 9.

Medicine

Channels:

American Society Of Hematology, Medical Research, Myelofibrosis, genetic-based prediction model

International Research Team Identifies Genetic-Based Model for Predicting Outcomes in Primary Myelofibrosis

A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease.

Medicine

Channels:

Using Software, Researchers Predict Tumor Markers That Could Be Immune Targets

vincent.jpeg

Researchers report at the 59th Annual American Society for Hematology Annual Meeting in Atlanta on Saturday, Dec. 9, that they were able to validate their approach for predicting markers – called minor histocompatibility antigens – in a group of patients with blood cancers.







Chat now!